Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting

[GlobeNewswire] – NOVATO, Calif. — Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of detailed … more

View todays social media effects on RARE

View the latest stocks trending across Twitter. Click to view dashboard

See who Ultragenyx is hiring next, click here to view